StockData
Takeda Pharmaceutical Co Ltd logo

Takeda Pharmaceutical Co Ltd

TAKNYSEPharmaceutical PreparationsAlso trades as TKPHF
Financials through fiscal 2026, year ended Mar 31, 2026Last filing: 20-F on Jun 17, 2026Score 5/30
$21.77+0.36 (+1.68%)

Close on Nov 20, 2026Market cap $75.03BP/E –Yield –

Takeda Pharmaceutical Adjusted EBITDA (Last Twelve Months / LTM) by Quarter

Periods

Takeda Pharmaceutical Adjusted EBITDA (Last Twelve Months / LTM): 1,540.30 JPY billion in Q2 FY27, up 13.8% from a year earlier. That is the highest of the 16 quarters on record here.

Latest, Q2 FY27
1,540.30
Period ended Sep 30, 2026 (CQ3 2026)
Change on a year earlier
+13.8%
1,353.90 in Q2 FY26
History
16 quarters
Since Q4 FY22
Sources
15
Documents cited below

Where the Q2 FY27 figure comes from

“|| Adjusted EBITDA (LTM) *5 | 1,540.3 | Net increase (decrease) in short-term loans and commercial papers | (341.8) | —”

Source: SEC EDGAR Filing (exhibit991_102926.htm) ↗

Reported in Form 6-K Exhibit 99.1 Quarterly Financial Appendix.

quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedAdjusted EBITDA (Last Twelve Months / LTM)Year on yearSource
Q2 FY27CQ3 2026Sep 30, 20261,540.30+13.8%SEC EDGAR Filing (exhibit991_102926.htm) ↗
Q1 FY27CQ2 2026Jun 30, 20261,503.80+9.6%SEC EDGAR Filing (exhibit991_073026.htm) ↗
Q4 FY26CQ1 2026Mar 31, 20261,457.20+1.1%SEC EDGAR Filing (exhibit991_051326.htm) ↗
Q3 FY26CQ4 2025Dec 31, 20251,404.50-4.5%SEC EDGAR Filing (exhibit991_012926.htm) ↗
Q2 FY26CQ3 2025Sep 30, 20251,353.90-7.2%SEC EDGAR Filing (exhibit991_103025.htm) ↗
Q1 FY26CQ2 2025Jun 30, 20251,372.40-0.7%SEC EDGAR Filing (exhibit991_073025.htm) ↗
Q4 FY25CQ1 2025Mar 31, 20251,441.00+9.2%SEC EDGAR Filing (exhibit991_050825.htm) ↗
Q3 FY25CQ4 2024Dec 31, 20241,471.00+8.2%SEC EDGAR Filing (exhibit991_013025.htm) ↗
Q2 FY25CQ3 2024Sep 30, 20241,459.20+3.8%SEC EDGAR Filing (exhibit991_103124.htm) ↗
Q1 FY25CQ2 2024Jun 30, 20241,382.40-3.9%SEC EDGAR Filing (exhibit991_073124.htm) ↗
Q4 FY24CQ1 2024Mar 31, 20241,319.90-7.2%SEC EDGAR Filing (exhibit991_050924.htm) ↗
Q3 FY24CQ4 2023Dec 31, 20231,358.90–SEC EDGAR Filing (exhibit991_020124.htm) ↗
Q2 FY24CQ3 2023Sep 30, 20231,406.20–SEC EDGAR Filing (exhibit991_102623.htm) ↗
Q1 FY24CQ2 2023Jun 30, 20231,438.80–SEC EDGAR Filing (exhibit991_072723.htm) ↗
Q4 FY23CQ1 2023Mar 31, 20231,421.80+21.7%SEC EDGAR Filing (exhibit991_051123.htm) ↗
Q4 FY22CQ1 2022Mar 31, 20221,168.00–SEC EDGAR Filing (exhibit991_051123.htm) ↗

Cite this data

StockData. (2026). Takeda Pharmaceutical Adjusted EBITDA (Last Twelve Months / LTM), quarterly Q4 FY22–Q2 FY27 [Data set]. Compiled from Takeda Pharmaceutical SEC filings and investor materials. https://stockdatahq.com/stocks/tak/kpis/sec-adj-ebitda-ltm

See every metric in the Takeda Pharmaceutical KPI table. Data updated Nov 10, 2026.

See a number that looks wrong?